Osinib (Osimertinib), general Tagrisso is a traditional drug used to treat advanced or metastatic epidermal growth factor receptor (EGFR) T790M mutation-positive non-small cell lung cancer (NSCLC). Osinib is manufactured by Drug InternationalLtd. in Bangladesh.
Have to take it orally formerly diurnal with or without food.
The most common adverse responses (≥ 25) are
Diarrhea, rash, dry skin, nail toxin, stomatitis, and reduced appetite.
The below information comes from the Internet. Please consult with the croaker for medical advice.
* Any advice on the use of the medicine is for reference only. Please consult with the croaker for medical advice. All Names, ensigns, and trademarks are the property of their separate possessors. Watermarks and QR canons are used for identification purposes only.